

The background features several complex molecular structures, likely representing pharmaceutical compounds, rendered in a 3D ball-and-stick model. The structures are primarily blue and purple, set against a dark background. They are arranged in a way that suggests a network or interconnectedness, with some structures appearing more prominent than others.

# Regeneron Corporate Presentation

J A N U A R Y 2 0 2 6

**REGENERON<sup>®</sup>**

This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.

# Note regarding forward-looking statements and non-GAAP financial measures

This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates"); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties or other factors beyond Regeneron's control on the commercial success of Regeneron's Products and Regeneron's Product Candidates; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and Regeneron's Product Candidates and research and clinical programs now underway or planned, including without limitation EYLEA HD® (afibercept) Injection 8 mg, EYLEA® (afibercept) Injection, Dupixent® (dupilumab), Libtayo® (cemiplimab), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab), Veopoz® (pozelimab), Orspono™ (odronextamab), Lynozytic™ (linvoseltamab), other clinical programs discussed in this presentation, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of the anticipated milestones discussed or referenced in this presentation; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as those listed above; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; Regeneron's ability to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement or copy assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron's drug pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; unanticipated expenses; the costs of developing, producing, and selling products; Regeneron's ability to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; Regeneron's estimates of market opportunities for Regeneron's Products and Regeneron's Product Candidates; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

This presentation includes or references non-GAAP EPS, net product sales growth on a constant currency basis for certain of Regeneron's Products and projected 2026 non-GAAP R&D expense, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). These and other non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. Management uses this and other non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations. However, there are limitations in the use of such non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures used in this presentation is provided on slide 34.

# REGENERON

SCIENCE TO MEDICINE®

**RGC**  
Regeneron Genetics Center

## Integrating Genetics, Proteomics, and Big Data

World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics



## Accelerating Innovation and R&D Productivity

Powerful toolkit of proprietary, turnkey technology platforms provides enduring competitive advantages

**VELOCIMMUNE®**  
Leaders in human antibodies

**VELOCI-BI®**  
Pioneers in bispecifics

Genetics Medicines

siRNA | gene editing | AAV gene therapy

## Following the Science

~45 clinical programs across six core therapeutic areas provides a strong foundation for future growth



## Delivering Breakthrough Medicines

14 internally-discovered therapies have been approved, poised to deliver many more...

**DUPIXENT**®  
(dupilumab)

**LIBTAYO**®  
(tremelimumab)

**LYNZOZYFC**®  
(lynestipiprant-pallidone)

**EYLEA HD**®  
(aflibercept) injection 2mg

**EYLEA**®  
(aflibercept) injection 2mg

**Leveraging the power of science to bring transformative medicines to patients... over and over again**

# Q4 2025 Financial Performance and Pipeline Developments



4Q25 Total Revenues

**\$3.9B**

4Q25 Non-GAAP EPS\*

**\$11.44**

## Notable R&D Pipeline Advancements



- Approved in Europe for CSU in patients who remain symptomatic despite antihistamine treatment
- Announced positive results from Phase 3 trial in AFRS; sBLA accepted for Priority Review (PDUFA February 2026)
- Approved in Japan for uncontrolled pediatric (6 -11 yrs) bronchial asthma



- Approved in U.S. and Europe for Macula Edema following RVO with dosing intervals of every-8-weeks after initial monthly doses
- FDA approved every-4-week (monthly) dosing option across all approved indications
- FDA approved new vial filler; regulatory application for new PFS filler submitted with FDA decision expected in Q2 2026



- Approved in U.S. and Europe for high-risk adjuvant CSCC

## Other Products and Programs

- Submitted regulatory applications for **garetosmab** in FOP in U.S. and Europe
- BLA submitted for **DB-OTO** to treat genetic hearing loss; FDA decision expected in 1H 2026

# Continued growth and expansion in multiple Type 2 indications

4Q 2025 Dupixent global net sales of \$4.9B (+32% YoY\*)

**>1.4 million** patients on therapy globally

Approved in **EIGHT** indications globally

**Chronic Spontaneous Urticaria (CSU)** approved by the EC (November 2025)


**CSU-Pediatric** sBLA accepted for review (April 2026 PDUFA)

**Bullous Pemphigoid (BP)** EC decision expected in 1H 2026

**Allergic Fungal Rhinosinusitis (AFRS)** sBLA accepted for priority review (February 2026 PDUFA)

**#1 position in both NBRx and TRx in all established indications, with CSU ramping post mid-2025 launch**

Dupixent global net product sales, in \$ Millions




Sanofi records global net product sales of Dupixent

# Strong launches in new indications while unlocking revenue growth through development balance repayment


New launches and repayment of development balance expected to drive Sanofi Collaboration Revenue growth in 2026

**Dupixent Cumulative NBRx by Indication**  
Weekly launch-aligned cumulative NBRx by indication over first 52 weeks



Data Source IQVIA Weekly NSOB, through December 26, 2025

**Reimbursement Obligation to Sanofi**  
(‘Antibody Development Balance’), in \$ Billions



Agreement restructured in 2022 as part of the acquisition of exclusive global rights to Libtayo; previously growing balance began to decline following close of the transaction (July 1, 2022)


**#1 prescribed biologic** among dermatologists, pulmonologists, allergists and ENTs

Strong momentum from recent respiratory (**COPD**) and dermatology (**CSU, BP**) launches

Expected to be **fully reimbursed by mid-2026**, unlocking significant collaboration revenue growth

# Delivering on Dupixent's "pipeline in a product" potential

Dupixent clinical trials have repeatedly demonstrated that IL-4 and IL-13 are key drivers of multiple Type 2 inflammatory diseases



**CSU approved in EU in Nov 2025, EC decision for BP expected in 1H 2026, AFRS PDUFA in Feb 2026, CSU-Pediatric PDUFA in Apr 2026**

# EYLEA HD + EYLEA in the U.S.


EYLEA HD + EYLEA remain the U.S. branded anti-VEGF category leader

## Goal to establish EYLEA HD as new standard of care for retinal diseases



- Q4 2025 U.S. net product sales of **\$506M**
- Comprised **nearly 50%** of Q4 2025 aggregate EYLEA + EYLEA HD U.S. net product sales
- Net sales driven by increasing demand (+10% q/q)
- Approval of RVO and Q4W dosing expected to accelerate demand growth in 2026
- Q1 2026 EYLEA HD sales expected to be negatively impacted by:
  - Typical seasonality for patient reauthorizations
  - Elevated inventory of ~\$30M at the end of Q4 2025, to be absorbed in Q1 2026

U.S. Net Product Sales, in \$ Millions



# Strengthening EYLEA HD's best-in-class profile

Recent label enhancements expected to broaden adoption to patients with RVO and to patients requiring more frequent dosing



## Monthly Dosing Option

- Offers physicians **greater flexibility** to tailor treatment for individual patient needs
- Best-in-class **durability** profile complemented with ability to treat patients who may require more frequent injections



## Macula Edema following Retinal Vein Occlusion

- EYLEA HD **every 8 weeks** delivers non-inferior visual gains vs. EYLEA every 4 weeks, plus flexibility for **treatment beyond 6 months**
- RVO represented **~20%** of EYLEA net sales in 2025



## Pre-Filled Syringe

- **FDA submission** for alternate PFS filler **completed** in December 2025 (2Q 2026 decision anticipated)
- **FDA approved** alternate vial filler in December 2025
- Strong physician preference with **95%** of EYLEA administered via PFS

**EYLEA HD is positioned to offer the broadest indication set and greatest dosing flexibility in the anti-VEGF category**

# Driving global Oncology growth through differentiated launches

Positive early launch progress with Libtayo in adjuvant CSCC and Linozyfic in r/r multiple myeloma



**Adjuvant CSCC**

*Only FDA- and EC-approved treatment*



Engaging with a **broader range of treating specialties** (Med-Oncs, Rad-Oncs, Mohs Surgeons, H&N Surgeons)



Libtayo is the only NCCN **Category 1 Preferred adjuvant CSCC** immunotherapy option for eligible patients, formulary wins accelerating uptake



**10,000+** eligible patients in the U.S. and EU



**r/r Multiple Myeloma**

*FDA accelerated approval  
EC conditional approval*



**300+** institutions have enrolled in the Linozyfic REMS program



Added to **50+** formularies and is the **preferred BCMA** bispecific at a major institution



**Differentiated profile:**  
~2x CR rates at similar follow-up, simplified dosing, and **less step-up dosing hospitalization**

# Key growth driver and foundational to oncology portfolio

Libtayo is the leading immunotherapy for advanced non-melanoma skin cancers; building share in advanced non small cell lung cancer

## Strong and consistent growth

- Q4 2025 global net sales of **\$425M (+13% YoY\*)**
- 2025 net sales of **\$1.45B (+17% YoY\*)**



Advanced  
**NSCLC**

- One of two PD-1 antibodies FDA-approved for use in combination with chemotherapy irrespective of histology or PD-L1 expression levels
- #2 most prescribed I/O treatment for advanced NSCLC in the U.S.



Advanced  
**BCC**

- Leading anti-PD-1/L1 therapy in advanced CSCC and BCC




Advanced  
**CSCC**

**First and only immunotherapy to show statistically significant DFS benefit in high-risk adjuvant CSCC**

**Global launch now underway**

Libtayo global net product sales,  
in \$ Millions



# R/R Multiple Myeloma: Lynozyfic provides a differentiated and compelling clinical profile in the BCMA bispecific class

There are no randomized, head-to-head clinical trials between these products. Study data being provided for descriptive purposes only. Caution is advised when drawing conclusions based on cross-trial comparisons.

	Teclistamab – FDA Approved (per U.S. FDA Prescribing Information <sup>§</sup> )	Elranatamab – FDA approved (per U.S. FDA Prescribing Information <sup>§</sup> )	<b>Lynozyfic – Now FDA approved</b> (per U.S. FDA Prescribing Information <sup>§</sup> )
<b>Efficacy</b>	ORR  62% sCR + CR  28% Follow-up 7.4-months among responders	ORR  58% sCR + CR  26% Follow-up 11.1-months among responders	200mg dose ORR  70% sCR + CR  45% Follow-up 11.3-months among responders
<b>Safety</b>	 CRS median time to onset: 2 days median duration: 2 days	 CRS median time to onset: 2 days median duration: 2 days	 CRS median time to onset: 11 hours median duration: within 15 hours
<b>Hospitalization, Administration &amp; Dosing schedule</b>	x 6 days 3 X 48-hr hospitalization requirements during step-up dosing (over initial ~9 days) Subcutaneous (by HCP only) QW → Q2W Week 1 - 6 months → 6+ months (≥CR only)	x 3 days 1 X 48-hr + 1 X 24-hr hospitalization requirements during step-up dosing (over initial ~5 days) Subcutaneous (by HCP only) QW → Q2W → Q4W Weeks 1-24 → Weeks 25-48 (responders) → Weeks 49+ (responders)	x 2 days 1 X 24-hrs in W1 + 1 X 24-hrs in W2; Hospitalized for 1 day during step-up dosing on <b>Day 1 &amp; Day 8</b> Intravenous (Week 3+ = 30-min*) QW → Q2W → Q4W Weeks 1-14 → Weeks 15-23 → Week 24+ if VGPR+

Not full safety profile. Please refer to U.S. FDA prescriber information and Regeneron's disclosures for further details

<sup>§</sup>US PI as of December 2025 † 4 hours for step-up doses and first full dose, 1 hour for second full dose, then 30-min as long as patient tolerability allows.

Lynozyfic is FDA-approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

# Regeneron pipeline targets large opportunities across therapeutic categories

## Ophthalmology

Cemdisiran (C5 siRNA) ± Pozelimab (C5 Ab)*	Geographic atrophy
REGN7041 (CD3)	Uveitis
Undisclosed Target	Glaucoma
Undisclosed Target	Thyroid Eye Disease, Graves



\$15B+

## Immunology & Inflammation

IL-13	Type 2 Indications
IL-4	Type 2 Indications
IL-4xIL-13 bispecific§	Type 2 Indications
REGN1908-1909 (FeID1)	Cat Allergy
REGN5713-5715 (BetV1)	Birch Allergy
Multiple Agents§	Food Allergy
Itepekimab (IL-33)†	COPD, CRSwNP
Undisclosed Target	Lupus, Sjogren's, PBC, others



\$50B+

## Oncology & Heme-Onc

Lynozoyfic (BCMAxCD3)	Multiple myeloma
Fianlimab (LAG3) + Libtayo (PD-1)	1L metastatic melanoma, adjuvant melanoma
Ordspono (CD20xCD3)	Lymphoma
Ubatamatab (MUC16xCD3)	Ovarian Cancer



\$60B+

## THERAPEUTIC AREAS



\$15B+

## Hematology

Cemdisiran (C5 siRNA) ± Pozelimab (C5 Ab)*	Paroxysmal nocturnal hemoglobinuria
REGN7508 <sup>CAT</sup> (FXI)	Post-TKR VTE, Cancer VTE, PICC-associated thrombosis, SPAF, PAD
REGN9933A <sup>2</sup> (FXI)	PICC-associated thrombosis, SPAF, PAD



\$50B+

## Cardiovascular & Metabolic Diseases

Olatorepatide (GIP/GLP-1)	Obesity, T2D
Olatorepatide (GIP/GLP-1) + Praluent (PCSK9)	Obesity, T2D with dyslipidemia
GLP-1 + Trevogrumab (GDF8)	Muscle Sparing
Nex-z (TTR)†	ATTR
MASH siRNA* (CIDEB, PNPLA3, HSD17B13)	MASH



\$15B+

## Neurology & Rare Diseases

Cemdisiran (C5 siRNA)*	gMG
DB-OTO (AAV-based gene therapy)	Hearing loss
Garetosmab (Activin A)	FOP
SNCA siRNA*	Parkinson's Disease
SOD1 siRNA*	ALS
MAPT (Tau) siRNA*	Alzheimer's Disease
HTT siRNA*	Huntington's Disease

Agreement with: \*Alnylam; †Intellia; †Sanofi  
§Clinical development to commence in 2027

# Sustaining I&I leadership and unlocking new growth opportunities

Leveraging learnings from Dupixent and disease biology to advance next-gen approaches to treat inflammatory diseases


## Pursuing multi-pronged approach to sustain I&I leadership into the next decade

### 'Lifecycle' opportunities

- Longer **Dupixent\*** dosing intervals
- **Novel long-acting IL-4Ra<sup>+</sup>** antibody
- Long-acting, fully-human **IL-13 & IL-4** antibodies with optimized binding properties
  - Expedited AD development plan for IL-13; FIH expected in 1H 2026
- Long-acting **IL-4xIL-13 bispecific**

### Investigating novel I&I targets

- **Itepekimab\* (IL-33)**: Advancing in respiratory indications with strong genetic associations
  - Phase 3 CRSwNP data anticipated in 2027
- Additional **genetic-defined targets** discovered by Regeneron Genetics Center, each with pipeline-in-a-product potential, expected to enter clinic in 2026-2027



## Advancing broader allergy pipeline into large commercial opportunities

### Allergen-specific antibody approaches

- **Cat (FelD1)** and **birch (BetV1)** allergy programs each demonstrated positive Phase 3 results in 2025
- Registration-enabling studies initiating in 2026 for both programs; data anticipated in 2027

### Severe IgE-mediated food allergy

- **Lynozytic (BCMAxCD3) + Dupixent\*** achieved proof-of-principle; demonstrated sustained >90% reductions in IgE in 4 of 4 evaluable patients
- Advancing **novel therapeutic candidates** to develop more-targeted and/or specific approaches to potentially **eliminate IgE-mediated allergies**; FIH expected by 2027

# Advancing allergy pipeline: positive Phase 3 results for two first-in-class allergen-blocking antibodies

Positive Phase 3 results for antibody-blockers of cat and birch allergies; additional Phase 3 studies initiating in 2026

## Vision for Cat and Birch Allergy Programs


Provide targeted efficacy, safety and convenience to address refractory ocular symptoms and improve patients' quality of life

## Ocular Allergen Challenge Phase 3 Results

Patients received direct ocular instillation of the allergen (cat dander or birch pollen) at day 8 following single SC administration of allergen-blocking antibodies or placebo

	Cat Allergy (REGN1908 + REGN1909)	Birch Allergy (REGN5713 + REGN5715)
<b>Ocular itch</b> reduction vs. placebo (primary endpoint)	52% (p<0.0001)	51% (p<0.0001)
<b>Conjunctival redness</b> reduction vs. placebo	39% (p<0.0001)	46% (p<0.0001)
<b>Skin prick reactivity</b> reduction vs. placebo	44% (p<0.0001)	44% (p<0.0001)
Safety	Generally well-tolerated with no serious treatment-related adverse events or AE's leading to discontinuation	
Additional Phase 3 development planned	1H26	YE 2025

## Opportunity to Address Population with High Unmet Need in U.S.



# Key late-stage programs positioned to deliver over the next few years

## Late-stage opportunities spanning multiple therapeutic areas

### FIANLIMAB + LIBTAYO

#### LAG-3 + PD-1

Combining two potentially best-in-class checkpoint inhibitors

- Potential for **differentiated efficacy** vs. current standards-of-care in **melanoma** without exacerbating safety

#### Program Status

Pivotal data from **1L metastatic melanoma** trial anticipated in **1H 2026**



#### BCMAxCD3

Transform the **multiple myeloma** treatment paradigm

- **Monotherapy** & simplified combinations in **early-line** myeloma settings
- Goal to **prevent** myeloma by treating precursor conditions

#### Program Status

**4 registrational studies underway**, 4 more expected to initiate in 2026  
Pivotal data anticipated starting in 2027

### CEMDISIRAN ± POZELIMAB

#### C5 siRNA ± C5 antibody

**PNH**: combination approach for complete C5 blockade and potentially best-in-class efficacy

**gMG**: siRNA monotherapy delivers potentially best-in-class efficacy and convenience

**GA**: monotherapy and combination approaches being explored

#### Program Status

**gMG**: on track for NDA submission in **Q1 2026**  
**PNH**: pivotal data expected in **Q4 2026/Q1 2027**  
**GA**: initial results from lead-in cohort anticipated in **2H 2026**

### REGN7508 & REGN9933

Two Factor XI antibodies allow for customized approach

**REGN7508<sup>cat</sup>**: **optimizes anticoagulation activity** with reduced bleeding risk vs. SOC

**REGN9933<sup>A2</sup>**: effective anticoagulation with further **reduced bleeding risk**

#### Program Status

**2 registrational studies underway**, 6 more expected to initiate in 2026  
Pivotal data anticipated starting in 2027

### OLATOREPATIDE (OLA) ± VARIOUS AGENTS

#### GIP/GLP-1, combinations

Multi-faceted approach including GIP/GLP-1

**Prioritizing combo with Praluent (PCSK9)**: potential to achieve >50% LDL lowering along with weight loss, dosed via similarly-convenient weekly injection as leading GLP-1s

#### Program Status

Phase 3 results for Ola in obesity in China\* expected in 1H 2026  
**Comprehensive global clinical development plan** initiating in 2026

\*Hansoh Pharmaceuticals retains development and commercialization rights to olatorepatide in China.

This slide contains investigational drug candidates that have not been approved by any regulatory authority.

# Combining two potentially best-in-class checkpoint inhibitors: Fianlimab (anti-LAG-3) & LIBTAYO (anti-PD-1)

Potentially differentiated 1L metastatic melanoma treatment option; additional data readouts across other settings expected in 1H 2026




























Anticipated Milestones:	1H 2026	Phase 3 1L metastatic melanoma data	Phase 3 adjuvant melanoma data (1 <sup>st</sup> interim)	Phase 2 1L NSCLC data	
	Pembrolizumab (anti-PD-1)	Nivolumab (anti-PD-1)	Ipilimumab (anti-CTLA4) + nivolumab	Relatlimab (anti-LAG-3) + nivolumab	Fianlimab + cemiplimab
	KEYNOTE-006 n=277 (Q3W)	RELATIVITY-047 n=359	CHECKMATE-067 n=314	RELATIVITY-047 n=355	Pooled POC Cohorts n=98
 <b>Efficacy</b>	ORR  33% CR  <b>6%</b> PR  27%	ORR  33% CR  <b>14%</b> PR  18%	ORR  50% CR  <b>9%</b> PR  41%	ORR  43% CR  <b>16%</b> PR  27%	ORR  57% CR  <b>25%</b> PR  33%
<b>mPFS (months)</b>	<b>4.1</b>	<b>4.6</b>	<b>11.7</b>	<b>10.1</b>	<b>24 (KM estimate)</b>
<b>mOS (months)</b>	Not Reached	34.1	Not Reached	Not Reached	Not Reached
 <b>Safety</b>	All TRAE  73% Grade 3-4 TRAE  10%	All TRAE  70% Grade 3-4 TRAE  10%	All TRAE  96% Grade 3-4 TRAE  59%	All TRAE  81% Grade 3-4 TRAE  19%	All TRAE  81% Grade 3-4 TRAE  23%
<b>Follow up</b>	OS: final analysis with an additional FU of 9 mo	At the time of the final OS analysis	Minimum FU: 9 mo for ORR, 28 mo for PFS, 48 mo for OS	At the time of the final OS analysis	Median FU: 23 mo
<b>Source</b>	KEYTRUDA U.S. FDA PI; Robert et al., 2015 NEJM	OPDUALAG U.S. FDA PI; Tawbi et al., 2022 NEJM	YERVOY & OPDIVO U.S. FDA PI; Wolchok et al., 2017 NEJM	OPDUALAG U.S. FDA PI; Tawbi et al., 2022 NEJM	ESMO 2024 Data


Table depicts randomized Phase 3 data for four FDA-approved treatments in 1L metastatic melanoma as well as pooled, post-hoc data from three independent cohorts from initial trial of fianlimab + cemiplimab; there are no randomized, head-to-head clinical trials between these products. Study data being provided for descriptive purposes only. Caution is advised when drawing conclusions based on cross-trial comparisons.

\*This slide contains investigational data for the combination of fianlimab + cemiplimab; this combination has not been approved by any regulatory authority. All other products listed are FDA-approved therapies.

# Advancing Fianlimab & LIBTAYO combination in melanoma and across several solid tumor cancers

Data anticipated from multiple studies in 1H 2026

		Phase 1	Phase 2	Phase 3
<b>Melanoma</b>	1L Metastatic Melanoma (vs. pembrolizumab)	Pivotal data in 1H26		
	1L Metastatic Melanoma (vs. nivolumab+relatlimab)	Enrolling		
	Adjuvant Melanoma	Enrollment complete – 1 <sup>st</sup> interim analysis in 1H26		
	Perioperative Melanoma	Enrolling		
<b>NSCLC</b>	Advanced NSCLC	Next analysis in 1H26		
	Perioperative NSCLC	Enrolling		
<b>Other solid tumors</b>	Perioperative HCC	Enrolling		
	1L HNSCC (PD-L1+; HPV+ and HPV-)	Initiating 1H26		
	Perioperative HNSCC	Initiating 2026		



# Lynozyfic strategy and long-term vision

Unlocking long-term value by redefining multiple myeloma treatment and prevention



## Establish

- Build market share in late-line myeloma through positive treatment experiences for patients and physicians
- Supported by best-in-class late-line data among BCMA bispecifics



## Advance

- Move to earlier lines of treatment with differentiated, simplified, patient-centric regimens
- Emerging clinical data supports earlier-line opportunities



## Prevent



- Differentiated strategy to address precursor conditions and prevent progression to myeloma
- Initial clinical data suggest paradigm-changing potential for Lynozyfic in precursor setting (HRSMM, ALA)

## Lynozyfic Vision

Transform the multiple myeloma treatment paradigm with convenient, simplified and less intense treatment regimens that increase physician optionality and provide **deep and durable responses** to early-line patients and ultimately **prevent progression** to malignant disease by treating precursor conditions

# Aiming to transform the multiple myeloma treatment landscape

4 registrational studies underway to potentially transform the treatment paradigm with convenient, simplified and less intense treatment regimens  
 At LYNZOZYFIC 200 mg monotherapy, 100% of evaluable patients (n=21) achieved MRD-negativity in HRSMM and 1L multiple myeloma



D: daratumumab (Darzalex); K: carfilzomib (Kyprolis); V: bortezomib (Velcade); R: lenalidomide (Revlimid); P: pomalidomide (Pomalyst/Imnovid); d: dexamethasone; E: elotuzumab (Empliciti); Isa: isatuximab (Sarclisa); S: Selinexor (Xpovio); PI: proteasome inhibitor.

# Comprehensive development plan across disease spectrum


Numerous pivotal studies planned or ongoing, with multiple readouts expected through 2027–2030 to support paradigm-shifting potential and a significant commercial opportunity

	Indication/ Setting	Study Name	Phase	Target Enrollment	Status	Registrational	Monotherapy or combination	Comparator	Dose duration	MRD-negativity results	PFS results
Late Line MM	4-5L RRMM	<a href="#">LINKER-MM1</a>	Phase 1/2	387	Approved in EU & US	✓	Monotherapy	N/A	TTP	Complete	Complete
	3L+ RRMM	<a href="#">LINKER-MM2</a>	Phase 1	317	Ongoing umbrella study		Combinations with multiple SoC	N/A	TTP	Ongoing	Ongoing
	3L+ RRMM	<a href="#">LINKER-MM3*</a>	Phase 3	410	Fully enrolled	✓	Monotherapy	EPd	TTP	2027*	2027
	3L+ RRMM	<a href="#">COSTIMM</a>	Phase 1	186	Enrolling		Combination with CD38xCD28	Linvo monotherapy	TTP	Ongoing	Ongoing
Early Line MM	2L+ RRMM	<a href="#">LINKER-MM5*</a>	Phase 3	30 (Part 1) 885 (Part 2)	Initiating 1Q 2026	✓	Monotherapy & combination with carfilzomib	Physicians choice SoC	TTP	2028*	2030
	1L NDMM	<a href="#">LINKER-MM4</a>	Phase 1/2	132	Enrolling; data presented at ASH 2025		Monotherapy	N/A	Fixed	Ongoing	Ongoing
	1L TIE	<a href="#">LINKER-MM6*</a>	Phase 3	1,000	Enrolling	✓	Monotherapy (after SoC debulking)	DRd	TTP	2028*	2030
	1L TE MM	<a href="#">LINKER-MM7*</a>	Phase 3	TBD	Initiating 1H 2026	✓	Monotherapy	SoC	Fixed	2028*	2030
	1L TE MM	<a href="#">LINKER-MM8*</a>	Phase 2/3	TBD	Initiating 1H 2026	✓	Combination	ASCT SoC	Fixed	2030*	2032
Myeloma Precursor / ALA	HR-MGUS / NHR-SMM	<a href="#">LINKER- MGUS1</a>	Phase 2	116	Enrolling		Monotherapy	N/A	Fixed	Ongoing	Ongoing
	HRSMM	<a href="#">LINKER-SMM1</a>	Phase 2	40	Enrolling		Monotherapy	N/A	Fixed	Ongoing	Ongoing
	HRSMM	<a href="#">LINKER-SMM2</a>	Phase 3	270	Initiating 1H 2026	✓	Monotherapy	D	Fixed	N/A	2030 <sup>‡</sup>
	ALA	<a href="#">LINKER-AL2</a>	Phase 1/2	160 – 220	Enrolling	✓	Monotherapy	N/A	Fixed	N/A	2029 <sup>‡</sup>

\*MRD-negativity expected to be registrational endpoint. <sup>‡</sup>Hematologic Complete Response is primary endpoint; <sup>‡</sup>Biochemical PFS is primary endpoint. TTP: treat to progression. Underline – linked to ClinicalTrials.gov; Timing of results are estimated

# Tailored C5 therapeutic approach: siRNA ± antibody provides flexibility to address multiple complement-mediated diseases

siRNA (cemdisiran) lowers C5 target burden while antibody (pezelimab) blocks circulating C5, enabling near-complete C5 inhibition



Differentiated siRNA ± antibody approach has pipeline-in-a-product potential to deliver tailored, effective, and convenient treatments across multiple complement-mediated diseases

# Cemdisiran (C5 siRNA): positive Phase 3 results demonstrate a competitive profile with differentiated dosing in the growing gMG category





\*There are no randomized, head-to-head clinical trials between these products. Study data being provided for descriptive purposes only. Caution is advised when drawing conclusions based on cross-trial comparisons.

**Cemdisiran monotherapy dosed every 3 months met primary and all key secondary endpoints**

**2.3-point placebo-adjusted improvement in MG-ADL**  
(Myasthenia Gravis Activities of Daily Living) **total score** at Week 24


➤ **The highest placebo-adjusted reduction observed among C5-inhibitors\***

**U.S. NDA submission planned for 1Q26**

	Current gMG Landscape	Regeneron Opportunity (Cemdisiran Monotherapy)
 <b>Market Opportunity</b>	<ul style="list-style-type: none"> <li>~90k U.S. patients</li> <li>~\$5Bn market in 2025 expected to grow at ~17% CAGR through 2030</li> </ul>	<ul style="list-style-type: none"> <li>Differentiated MOA with C5-inhibiting siRNA monotherapy</li> </ul>
 <b>Efficacy</b>	<ul style="list-style-type: none"> <li>Modest improvement in MG-ADL scores with C5 inhibitors</li> <li>Rapid symptom rebound after dosing cycles with FcRn inhibitors</li> </ul>	<ul style="list-style-type: none"> <li>Best observed efficacy in MG-ADL reductions among C5 inhibitors*</li> <li>More durable MG-ADL reduction with similar depth of response compared to FcRn inhibitors*</li> </ul>
 <b>Route of Administration</b>	<ul style="list-style-type: none"> <li>Leading C5 antibodies dosed IV Q2W - Q8W</li> <li>FcRn inhibitors dosed IV/SC QW in 4-week cycles</li> </ul>	<ul style="list-style-type: none"> <li>Convenient Q12W SC dosing</li> <li>Opportunity to move to self-administration with PFS and/or autoinjector after initial launch in vials</li> </ul>
 <b>Safety</b>	<ul style="list-style-type: none"> <li>Higher rates of severe TEAEs relative to cemdisiran in clinical trials*</li> <li>Higher rates of treatment discontinuation relative to cemdisiran in clinical trials*</li> </ul>	<ul style="list-style-type: none"> <li>Cemdisiran monotherapy arm demonstrated no meningococcal infections and no treatment discontinuations through 24 weeks</li> <li>Lower rates of severe TEAEs relative to leading C5 antibody and FcRn inhibitors*</li> </ul>

# Tailored approach to anticoagulation treatment with differentiated Factor XI program

Regeneron's two antibodies allow customized approach: **REGN7508<sup>Cat</sup>** optimizes anticoagulation activity with potential for reduced bleeding risk vs. SOC, **REGN9933<sup>A2</sup>** further reduces bleeding risk with comparable anticoagulation vs. SOC



## Anticipated therapeutic profile

	Anticoagulation potency	Bleeding risk	Most suitable for:
<b>REGN9933<sup>A2</sup></b>			<b>Patients with highest bleeding risk</b> Indications: AF DOAC Non-Candidates, patients on background dual antiplatelet therapy (PAD)
<b>REGN7508<sup>Cat</sup></b>			<b>Patients requiring maximal anticoagulation</b> Indications: VTE, AF DOAC Candidates
<b>DOACs</b>			Approved for several anticoagulation indications

For illustrative purposes only

# Addressing the bleeding risk in anticoagulation treatment: Regeneron's broad Factor XI clinical program

\$20B anticoagulation market remains underpenetrated due to bleeding risk; <50% of eligible patients receive therapy because of safety concerns



Post-TKR VTE

**R7508**

Two trials enrolling, data expected in 2027



Cancer VTE

**R7508**

Trials initiating in 1H 2026, data expected in 2029+



PICC-associated Thrombosis

**R7508**

**R9933**

Trial to initiate in 2026, data expected in 2028+



Stroke Prevention in AF

**R7508**

**R9933**

Phase 2 enrolling, data expected in 2027  
Phase 3 trials to initiate in 2026




Peripheral Artery Disease

**R7508**


**R9933**

Trial initiating in 1H 2026, initial data expected in 2029+


## Phase 2 results in VTE prevention post-knee replacement surgery support broad Phase 3 development



## Interim Phase 2 results in catheter-associated thrombosis support development in contact-mediated settings








## Phase 1 GI Bleed Study results support favorable bleeding profile in a healthy volunteer provoked bleeding model



To date, no major bleeding events observed in Phase 1 or Phase 2 studies due to REGN7508 or REGN9933

# Broad Factor XI development program advancing rapidly

Genetics, preclinical, and clinical data support broad Factor XI development

	Patient Segment	Study	Target Enrollment	Treatment Period	Est. Study Start	Est. Primary Completion	
	<b>Post-Total Knee Replacement (TKR) VTE</b> U.S. ~2M	<b>ROXI-APEX</b> (Cat vs. apixaban vs. enoxaparin)	~2,000	Single dose	enrolling	1Q 2027	
		<b>ROXI-ASPEN</b> (Cat vs. aspirin)	~2,000	Single dose	enrolling	2027	
	<b>Primary prevention</b> 100k	<b>ROXI-CAT I</b> (Cat vs. placebo)	~850	6 mos	1H26	2029 +	
	<b>Secondary prevention</b> 850k	<b>ROXI-CAT II</b> (Cat vs. apixaban)	~1,500	6 mos +	1H26	2029 +	
	<b>Stroke Prevention in Atrial Fibrillation (SPAF)</b> U.S. ~8M	<b>DOAC candidates</b> ~6.4M (80%)	<b>ROXI-ATLAS Ph2*</b> (Cat vs. A2 vs. apixaban)	~1,200	3 mos	enrolling	2Q 2027
			<b>ROXI-EVEREST</b> (Cat vs. apixaban)	~15,000	16-36 mos	2026	2029 +
	<b>DOAC non-candidates</b> ~1.6M (20%)	<b>ROXI-INCLINE</b> (Cat vs. A2 vs. placebo)	~2,650	12-36 mos	1H26	2028 +	
	<b>Peripherally Inserted Central Catheter (PICC)-Associated Thrombosis</b>	<b>ROXI-PEAK</b> (Cat and A2 vs. placebo)	~2,050	Duration of PICC line	2026	2028 +	
	<b>Peripheral Artery Disease (PAD) Post-Revascularization</b> U.S. ~310k	<b>ROXI-PALISADE</b> (Cat vs. A2 vs. rivaroxaban or placebo)	~7,050	~19 mos	1H26	2029 +	

# Transforming patient care for obesity and related conditions

Three major opportunities for Regeneron in the rapidly growing obesity therapeutic area

1



## GIP/GLP-1 Receptor Agonist monotherapy

In-licensing of olatorepatide (dual GIP/GLP-1 receptor agonist) enables initial monotherapy development

- Phase 3 program in obesity with and without T2D to initiate in 2026

Monotherapy

2



## Address obesity comorbidities with novel combinations

Initiating olatorepatide-Praluent (PCSK9) program in 2026:

- Approved GLP-1s lower LDL-C by less than 10%
- Combination to potentially achieve >50% LDL lowering along with weight loss
- To be administered via similarly-convenient weekly injection as leading GLP-1s

Novel combinations

3



## Enhancing the quality of GLP-1-based weight loss



- Harness beneficial effects of muscle preservation in obesity
- POC data on anti-myostatin ± anti-activin A warrant potential future development
- Unimolecular solutions in preclinical development

Improving quality of weight loss

# World-class Regeneron Genetic Medicines (RGM) Program

RGM builds and utilizes 'turnkey' therapeutic platforms – customizing the choice of genetics technology (siRNA, CRISPR/Cas9, etc.) based on therapeutic application


Continuing to build in-house expertise and leverage groundbreaking industry collaborations



**Alnylam:** Exclusive siRNA collaboration in eye and CNS, with liver programs in MASH and additional RGC targets

**In-House:** Developing next-generation gene therapies combining novel payloads, viral vectors and antibodies to address difficult-to-treat diseases

**Intellia:** Exclusive CRISPR/Cas9 gene knockdown and gene insertion in the liver and *ex vivo* targets




**Mammoth Biosciences:** Ultracompact CRISPR gene editing systems to advance *in vivo* programs in multiple tissue and cell types

**Tessera Therapeutics:** Global collaboration to develop and commercialize TSRA-196, Tessera's lead investigational *in vivo* Gene Writing program for the treatment of alpha-1 antitrypsin deficiency

# Regeneron Genetic Medicines pipeline



# Regeneron-discovered, approved and investigational medicines across a diverse set of diseases



Agreement with: <sup>†</sup>Sanofi; <sup>‡</sup>Alnylam; <sup>°</sup>Intellia; <sup>\*</sup>Bayer; <sup>\*\*</sup>Ultragenyx; <sup>†</sup>Kiniksa is solely responsible for development and commercialization of ARCALYST; <sup>§</sup>Sanofi is solely responsible for development and commercialization of ZALTRAP; <sup>Δ</sup>Discovered by Decibel Therapeutics.

As of January 2026; ALN-SOD is on U.S. FDA clinical hold, enrolling ex-U.S.; enrollment in ATTR-CM trial of Nex-z on FDA clinical hold. All trademarks mentioned are the property of their respective owners.

This slide contains investigational drug candidates that have not been approved by any regulatory authority.

# 2026 key milestones

## Ophthalmology

- **EYLEA HD**: pre-filled syringe (PFS) FDA decision (2Q26)
- **Cemdisiran ± pozelimab**: interim results from lead in cohort of Phase 3 trial in GA (2H26)

## Immunology & Inflammation

- **Dupixent**: EC decision for BP (1H26), FDA decision for AFRS (1Q26)
- **IL-13**: Initiate clinical program in atopic dermatitis (1H26)
- **R5713-5715**: Initiate second Phase 3 trial for birch allergy ✓
- **R1908-1909**: Initiate second Phase 3 trial for cat allergy (1H26)

## Cardiovascular & Metabolic Diseases

- **Olatorepatide (monotherapy)**: Initiate Phase 3 program in obesity with and without T2D (2026)
- **Olatorepatide + Praluent**: Initiate clinical program (2026)
- **Muscle preservation**: Report additional data from proof-of-concept data of combination of semaglutide and trevogrumab with and without garetosmab in obesity (2026)

## Hematology

- **R7508/R9933**: Initiate additional Phase 3 studies in anticoagulation (1H26)
- **Cemdisiran + Pozelimab**: report results from Phase 3 trial in PNH (4Q26 / 1Q27)

## Oncology & Heme-Onc

### Solid Oncology

- **Fianlimab + cemiplimab**: Report results in 1L metastatic melanoma from Phase 3 trial (1H26)
- **Fianlimab + cemiplimab**: Report initial Phase 2 data in 1L advanced NSCLC (1H26)

### Heme-onc

- **Lynozytic**: Initiate additional Phase 3 studies in multiple myeloma and precursor conditions (2026)

## Neurology & Rare Diseases

- **Cemdisiran**: NDA submission for gMG (1Q26); FDA decision (4Q26 / 1Q27)
- **DB-OTO**: FDA decision for genetic hearing loss (1H26)
- **Garetosmab**: FDA and EC decisions in FOP (2H26)

# Deploying capital to maximize long-term value creation

Disciplined capital allocation approach laying the foundation for Regeneron's next wave of innovation

## Internal Investment



Investing in world-class R&D capabilities and infrastructure to support sustainable growth

**~\$6B** Non-GAAP R&D\* spend expected in 2026

**\$9B+** committed to U.S. manufacturing and R&D infrastructure expansion over the coming years

## Business Development



Leveraging external innovation to complement internal R&D

Expand through **complementary opportunities** across early and late development stages

- Collaboration with Alnylam, including in-licensing of **cemdisiran (C5 siRNA)**
- **GLP-1/GIP** in-licensed for obesity franchise expansion<sup>†</sup>
- Global collaborations for investigative **gene editing** therapies with Intellia, Mammoth and Tessera<sup>‡</sup>

## Return Capital to Shareholders



Rewarding shareholders through opportunistic share repurchases and dividends

**\$3.8B** Capital returned to shareholders in 2025<sup>§</sup>

~**\$3.4B** share repurchases  
~**\$0.4B** dividends

Quarterly dividend initiated in 2025;

Next quarterly dividend to be paid March 5, 2026 (**\$0.94/share**)

\*Based on most recent 2026 non-GAAP R&D guidance. See reconciliation of non-GAAP measure on slide 34. <sup>†</sup> License agreement with Hansoh Pharma.

<sup>‡</sup> Global collaboration with Tessera Therapeutics, Inc. is subject to customary closing conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. <sup>§</sup> As of December 31, 2025, ~\$1.5B was remaining under current share repurchase program.

# Our philosophy: Do well by doing good

We're focused on using the unique knowledge and expertise within our company to address the issues that matter most to our business and to our stakeholders.



## IMPROVING THE LIVES OF PEOPLE WITH SERIOUS DISEASES

- Pipeline innovation
- Access to medicine and fair pricing
- Patient advocacy
- Compassionate use



## FOSTERING A CULTURE OF INTEGRITY & EXCELLENCE

- Product quality and safety
- Diverse, healthy and engaged workforce
- Ethics and integrity
- Responsible supply chain



## BUILDING SUSTAINABLE COMMUNITIES

- STEM education—sponsorship of top science competitions:
  - Regeneron Science Talent Search
  - Regeneron International Science and Engineering Fair
- Environmental sustainability
- Volunteerism



# GAAP to Non-GAAP Reconciliations

REGENERON PHARMACEUTICALS, INC.  
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited)  
(In millions, except per share data)

	Three Months Ended December 31,		Year Ended December 31,	
	2025	2024	2025	2024
GAAP R&D	\$ 1,626.1	\$ 1,412.1	\$ 5,850.2	\$ 5,132.0
Stock-based compensation expense	140.3	174.7	545.4	543.8
Acquisition and integration costs	—	13.8	—	24.9
Priority review voucher	155.0	—	155.0	—
Non-GAAP R&D	\$ 1,330.8	\$ 1,223.6	\$ 5,149.8	\$ 4,563.3
GAAP SG&A	\$ 775.0	\$ 792.2	\$ 2,700.0	\$ 2,954.4
Stock-based compensation expense	83.9	103.1	362.9	355.0
Acquisition and integration costs	—	5.5	0.8	42.2
Litigation settlements	—	3.0	25.0	13.0
Non-GAAP SG&A	\$ 691.1	\$ 680.6	\$ 2,311.3	\$ 2,544.2
GAAP COGS	\$ 318.7	\$ 326.8	\$ 1,140.8	\$ 1,087.3
Stock-based compensation expense	25.1	26.6	85.4	84.0
Acquisition and integration costs	—	0.3	—	2.0
Intangible asset amortization expense	36.9	29.1	131.7	103.5
Non-GAAP COGS	\$ 256.7	\$ 270.8	\$ 923.7	\$ 897.8
GAAP other operating (income) expense, net	\$ —	\$ 15.5	\$ (10.0)	\$ 53.4
Change in fair value of contingent consideration	—	15.5	—	53.4
Non-GAAP other operating (income) expense, net	\$ —	\$ —	\$ (10.0)	\$ —
GAAP other income (expense), net	\$ 163.8	\$ (32.1)	\$ 1,652.8	\$ 789.2
Losses (gains) on marketable and other securities, net	21.5	212.9	(946.1)	(118.3)
Non-GAAP other income (expense), net	\$ 185.3	\$ 180.8	\$ 706.7	\$ 670.9
GAAP net income	\$ 844.6	\$ 917.7	\$ 4,504.9	\$ 4,412.6
Total of GAAP to non-GAAP reconciling items above	462.7	584.5	360.1	1,103.5
Income tax effect of GAAP to non-GAAP reconciling items	(91.4)	(112.5)	(54.4)	(196.9)
Income tax expense: Shortfall from stock-based compensation	32.6	—	32.6	—
Income tax expense: Charge related to enactment of OBBBA	—	—	44.5	—
Non-GAAP net income	\$ 1,248.5	\$ 1,389.7	\$ 4,887.7	\$ 5,319.2
Non-GAAP net income per share - basic	\$ 12.13	\$ 12.92	\$ 46.73	\$ 49.30
Non-GAAP net income per share - diluted	\$ 11.44	\$ 12.07	\$ 44.31	\$ 45.62
<i>Shares used in calculating:</i>				
Non-GAAP net income per share - basic	102.9	107.6	104.6	107.9
Non-GAAP net income per share - diluted	109.1	115.1	110.3	116.6

## Q4 2025 vs Q4 2024

Total Dupixent Net Product Sales - Outside the U.S.	
% growth as reported	27%
% growth at constant currency	21%
Total Dupixent Net Product Sales - Global	
% growth as reported	34%
% growth at constant currency	32%
Total Libtayo Net Product Sales - Outside the U.S.	
% growth as reported	21%
% growth at constant currency	12%
Total Libtayo Net Product Sales - Global	
% growth as reported	16%
% growth at constant currency	13%
Total EYLEA & EYLEA 8mg Net Product Sales - Outside the U.S.	
% growth as reported	(8%)
% growth at constant currency	(12%)

## FY 2025 vs FY 2024

Total Libtayo Net Product Sales - Global	
% growth as reported	19%
% growth at constant currency	17%

	Projected Range	
	Low	High
GAAP R&D	\$ 6,450	\$ 6,680
Stock-based compensation expense	550	580
Non-GAAP R&D <sup>(a)</sup>	\$ 5,900	\$ 6,100

(\$ in millions)

# Abbreviations and Definitions

Abbreviation	Definition
1L	First line
2L	Second line
3L+	Third line and beyond
AAV	Adeno-associated virus
AD	Atopic dermatitis
AFRS	Allergic fungal rhinosinusitis
ALA	Light chain amyloidosis
ALS	Amyotrophic lateral sclerosis
ASCT	Autologous stem cell transplant
ASH	American Society of Hematology
ATTR	Transthyretin amyloidosis
BCC	Basal cell carcinoma
BCMA	B-cell maturation antigen
BP	Bullous pemphigoid
CAR-T	Chimeric antigen receptor T-cell
CFB	Complement Factor B
COPD	Chronic obstructive pulmonary disease
CPUO	Chronic pruritus of unknown origin
CR	Complete response
CRS	Cytokine release syndrome
CRSwNP	Chronic sinusitis with nasal polyposis
	Chronic sinusitis with
CRSwNP	nasal polyposis
	Cutaneous squamous
CSCC	cell carcinoma
CSU	Chronic spontaneous urticaria
DFS	Disease-Free Survival

Abbreviation	Definition
DOAC	Direct oral anticoagulants
EC	European Commission
EGFR	Epidermal growth factor receptor
	Ear, Nose & Throat doctors (otolaryngologists)
ENT	
EoE	Eosinophilic Esophagitis
ESMO	European Society for Medical Oncology
	Neonatal fragment crystallizable receptor
FcRn	
FIH	First in human
	Fibrodysplasia Ossificans Progressiva
FOP	
GA	Geographic atrophy
GI	Gastrointestinal
GIP	Gastric inhibitory polypeptide
GLP-1	Glucagon-like peptide 1
gMG	Generalized myasthenia gravis
HCC	Hepatocellular carcinoma
HCP	Healthcare Provider
HNSCC	Head and neck squamous
HPV	Human papillomavirus
HRSM	High-risk smoldering multiple myeloma
HTT	Huntington
ICANS	Immune effector cell-associated neurotoxicity syndrome
IgE	Immunoglobulin-E
I/O	Immuno-oncology
LAG-3	Lymphocyte-activation gene 3
LEPR	Leptin receptor

Abbreviation	Definition
LDL/LDL-C	Low-Density Lipoprotein / Low-Density Lipoprotein-Cholesterol
MAPT	Microtubule-associated protein tau
MASLD	Metabolic dysfunction-associated steatotic liver disease
	Metabolic Dysfunction-Associated Steatohepatitis
MASH	
MGUS	Monoclonal gammopathy of unknown significance
MG-ADL	Myasthenia gravis activities of daily living score
MM	Multiple myeloma
MRD	Minimal residual disease
MOA	Mechanism of Action
(m)OS	(Median) overall survival
(m)PFS	(Median) progression-free survival
MUC16	Mucin 16
NBRx	New-to-brand prescriptions
NCCN	National Comprehensive Cancer Network
NDA	New Drug Application
NDMM	Newly-diagnosed multiple myeloma
NEJM	New England Journal of Medicine
	Non-high-risk smoldering multiple myeloma
NHR-SMM	
NSCLC	Non-small cell lung cancer
ORR	Overall Response Rate
PAD	Periperal artery disease
PCB	Primary Biliary Cholangitis
PD-1/PD-(L)1	Programmed cell death protein/(ligand) 1
PDUFA	Prescription Drug User Fee Act

Abbreviation	Definition
PFS	Pre-filled syringe
PI	Prescribing information
PNH	Paroxysmal nocturnal hemoglobinuria
POC	Proof-of-concept
PR	Partial response
PSMA	Prostate-specific
	Risk Evaluation and Mitigation Strategy
REMS	
RGC	Regeneron Genetics Center
R/R	Relapsed/Refractory
RRMM	Relapsed/Refractory multiple myeloma
RVO	Retinal vein occlusion
(s)BLA	(Supplemental) biologics license application
SC	Subcutaneous
sCR	Stringent complete response
siRNA	Small interfering RNA
SOC	Standard of care
SPAF	Stroke Prevention in Atrial Fibrillation
T2D	Type 2 diabetes
TE	Transplant Eligible
TEAE	Treatment-emergent adverse events
TIE	Transplant Ineligible
TKR	Total knee replacement
TRAE	Treatment-related adverse events
TRx	Total prescriptions
VGPR	Very good partial response
VTE	Venous thromboembolism